Vivos Therapeutics, Inc. (NASDAQ:VVOS – Get Rating) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 48,000 shares, a decline of 82.9% from the February 13th total of 281,000 shares. Based on an average daily volume of 2,700,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.2% of the company’s shares are short sold.
Vivos Therapeutics Trading Down 3.2 %
NASDAQ VVOS opened at $0.35 on Friday. The stock has a market cap of $8.65 million, a PE ratio of -0.29 and a beta of 2.83. Vivos Therapeutics has a 12 month low of $0.31 and a 12 month high of $2.99. The stock’s 50 day moving average is $1.04 and its 200 day moving average is $0.84.
Vivos Therapeutics (NASDAQ:VVOS – Get Rating) last posted its quarterly earnings data on Tuesday, December 20th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $4.25 million for the quarter. Vivos Therapeutics had a negative return on equity of 142.18% and a negative net margin of 155.58%. On average, analysts forecast that Vivos Therapeutics will post -1.06 EPS for the current fiscal year.
Institutional Trading of Vivos Therapeutics
Analysts Set New Price Targets
A number of brokerages recently commented on VVOS. Roth Capital reissued a “buy” rating on shares of Vivos Therapeutics in a research report on Wednesday, December 21st. Ascendiant Capital Markets assumed coverage on Vivos Therapeutics in a research report on Tuesday, January 17th. They set a “buy” rating on the stock.
Vivos Therapeutics Company Profile
Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
- Get a free copy of the StockNews.com research report on Vivos Therapeutics (VVOS)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.